Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain
TerminatedPhase 4NCT01743976
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Based on laboratory studies, donepezil will improve pain relief more than placebo in patients with chronic neuropathic pain who are currently taking gabapentin or pregabalin.
Study details
- Official title
- Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain
- Conditions
- Interventions
- Drug: Donepezil
- Drug: Placebo
- Sponsor
- Wake Forest University
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- Organization
- Wake Forest University Health Sciences
- Start date
- 2012-12
- Primary completion
- 2013-10-23
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosis of diabetic neuropathy or failed back syndrome with neuropathic symptoms * Age 18-80 * Taking a stable dose of gabapentin or pregabalin Exclusion Criteria: * Pregnant women or women of child-bearing potential not willing to practice a reliable form of birth control * Allergy to donepezil or other piperidine derivatives (including fentanyl, alfentanil, sulfentanil, remifentanyl, demerol, tramadol, loperamide, diphenoxylate, betaprodine, alphaprodine, ethopropazine, anileridine, piminodine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP),loratadine, fexofenadine * Unstable medical conditions including cardiac, pulmonary, renal or hepatic diseases that, in the opinion of the investigator, would preclude patients from finishing the trial * Any person with pending litigation * A history of major psychosis requiring hospitalization within the last three years * Non-English speaking, illiterate, unable to comprehend consent * Lack of contact information * Uncontrolled narrow-angle glaucoma * Currently being treatment with thioridazine (Mellaril) * Patients taking opioids will be excluded if they are taking a dosage that exceeds an equivalent of 30 mg of morphine per day * Patients taking more than one regular (not rescue) medication for pain * Patients taking donepezil for dementia * Patients with a baseline pain score less than 2 (0-10 scale) or greater than 8 (0-10) will be excluded
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01743976